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INTRODUCTION: 
The development of sustain release dosage form can 
achieve the aim of releasing the drug slowly for a long 
period but this is not sufficient to get sustained 
therapeutic effect. They may be cleared from the site of 
absorption before emptying the drug content. Instead, 
the mucoadhesive dosage form will serve both the 
purposes of sustain release and presence of dosage form 
at the site of absorption. In this regard, our review is 
high lighting few aspects of mucoadhesive drug 
delivery systems. 
Nasal administration offers an interesting alternative for 
achieving systemic drug effects to the parenteral route, 
which can be inconvenient or oral administration, which 
can result in unacceptably low bioavailabilities. The 
nasal epithelium is a highly permeable monolayer, the 
sub mucosa is richly vascularized, and hepatic first-pass 
metabolism is avoided after nasal administration. Other 
attractive features include the rather large surface area 
of the nasal cavity and the relatively high blood flow, 
which promotes rapid absorption.
1
 In the early 1980s, 
the concept of mucosal adhesives, or mucoadhesives, 
was introduced into the controlled drug delivery area. 
Mucoadhesives are synthetic or natural polymers that 
interact with the mucus layer covering the mucosal 
epithelial surface and main molecules constituting a 
major part of mucus. The concept of mucoadhesives has 
alerted many investigators to the possibility that these 
polymers can be used to overcome physiological 
barriers in long-term drug delivery. Extensive research 
efforts throughout the world have resulted in significant 
advances in understanding the various aspects of 
mucoadhesion. The research on mucoadhesives, 
however, is still in its early stage, and further advances 
need to be made for the successful translation of the 
concept into practical application in controlled drug 
delivery.
2 
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ABSTRACT: 
This review explains some aspects of mucoadhesion related to the nasal drug delivery system. On the first count, the theories of 
the adhesion of mucoadhesive polymers to the mucosa epithelium are described. Secondly, the characteristics and application 
of several widely used mucoadhesive polymers in nasal drug delivery are presented. The nasal mucosa provides a potentially 
good route for systemic drug delivery. One of the most important features of the nasal route is that it avoids first-pass hepatic 
metabolism, thereby reducing metabolism. The application of mucoadhesive polymers in nasal drug delivery systems has 
gained to promote dosage form residence time in the nasal cavity as well as improving intimacy of contact with absorptive 
membranes of the biological system. The aspiration of any drug delivery system is to endow with a therapeutic amount of drug 
to the proper site in the body to achieve promptly & then uphold the desired drug concentration. That is why the drug delivery 
system should deliver drug at a state dictated by the needs of the body over a specified period of treatment. This idealized 
objective points to the two aspects most important to drug delivery, namely, spatial placement relates to targeting a drug to a 
specific organ or tissue while temporal delivery refers to the control of rate of drug delivery to the target tissue. Over the last 
few decades, the relevance of mucoadhesive polymers in nasal drug delivery systems has gained significance among 
pharmaceutical scientists as a means of promoting dosage form residence time in the nasal cavity as well as for improving 
intimacy of contact with absorptive membranes of the biological system. In addition, the improved paracellular absorption 
subsequent the swelling of the mucoadhesive polymers on the nasal membranes provides an important way for the absorption 
of the macromolecules through the nasal cavity. 
Keywords: Nasal route, Mucoadhesive polymers, Paracellular absorption 
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Nasal administration offers an interesting alternative for 
achieving systemic drug effects to the parenteral route, 
which can be inconvenient or oral administration, which 
can result in unacceptably low plasma drug levels. 
Conventionally the nasal cavity is used for the treatment 
of local diseases, such as rhinitis and nasal congestion. 
However, in the past few decades, nasal drug delivery 
has been paid much more attention as a promising drug 
administration route for the systemic therapy. This is 
due to the anatomy and physiology of the nasal passage, 
such as, the large surface area, highly vascularized 
epithelium, porous endothelial membrane, and the 
avoidance of first-pass metabolism.
3,4
 
Despite the high permeability of nasal membrane, 
generally, only small molecular weight drugs (<1000 
Da) show adequate absorption in the nasal cavity, most 
hydrophilic and macromolecular drugs such as insulin 
show low bioavailability or even no abrosrption.
5, 6
 The 
main reason for this is that they are lowly permeable 
and susceptible to the proteases in the nasal mucosal 
membrane, so these drugs can be rapidly cleared from 
the cavity, by ciliary movement or enzymatic 
degradation before they reach the bloodstream, and 
cannot cross the mucosal barriers. Penetration 
enhancers such as surfactants bile salts, fusidate 
derivatives and phospholipids 
7, 8, 9, 10, 11
 have been used 
to improve the drug absorption through nasal mucosa, 
but toxicity tests have proved that they were of limited 
clinical use because of their irreversible damage to 
nasal mucosa accompanied with their absorption-
enhancing effects. 
12, 13
 
Benefits and Precincts of nasal drug delivery: 
Benefits:
14 
 Avoids degradation of drug in gastrointestinal tract 
resulting from acidic or enzymatic degradation 
 Avoids degradation of drug resulting from hepatic 
first-pass metabolism 
 Results in rapid absorption and onset of action 
 Results in higher bioavailability thus needing lower 
doses of drug 
 Easily accessible, non-invasive route 
 Self-medication is possible through this route 
 Direct transport into systemic circulation and CNS 
is possible 
 Offers lower risk of overdose 
 Does not have any complex formulation 
requirement 
 Unlike the skin, nasal mucosa is not constructed 
from the keratinized stratum corneum. The 
subepithelial layer of the nasal mucosa with 
numerous microvilli is highly vascularized, with 
large and fenestrated capillaries facilitating rapid 
absorption. 
 The rate and extent of absorption as well as plasma 
concentration vs time profiles are comparable with 
I.V. administration. 
Precincts:
 14 
 Nasal atrophic rhinitis and severe vasomotor 
rhinitis can reduce the capacity of nasal absorption, 
e.g., Caerulein. 
 There could be mechanical loss of the dosage form 
into the other parts of the respiratory tract like 
lungs. 
 Volume that can be delivered into nasal cavity is 
restricted to 25–200 μl 
 High molecular weight compounds cannot be 
delivered through this route (mass cut off ~1 kDa) 
 Adversely affected by pathological conditions. 
 Large interspecies variability is observed in this 
route. 
 Normal defence mechanisms like mucociliary 
clearance and ciliary beating affects the 
permeability of drug. 
 Enzymatic barrier to permeability of drugs. 
Mucoadhesion/Bioadhesion:
 15, 16 
Good defined mucoadhesion as the state in which two 
materials, at least one biological in nature, 
are held together for an extended period of time by 
interfacial forces .It is also defined as the ability of a 
material (synthetic or biological) to adhere to a 
biological tissue for an extended period of time. In case 
of mucoadhesion, the biological tissue is the mucous 
membrane. For mucoadhesion to occur, a succession of 
phenomena is required. The first stage involves an 
intimate contact between a mucoadhesive polymer and 
a membrane, either from good wetting of the 
mucoadhesive surface or from the swelling of the 
mucoadhesive. In the second stage, after contact is 
established, penetration of the mucoadhesive into the 
crevice of the tissue surface or interpenetration of the 
chains of the mucoadhesive with those of the mucus 
takes place. Low chemical bonds can then settle. 
Mucoadhesive polymers Mucoadhesive polymers are 
water soluble and water insoluble polymers, which are 
swellable networks, jointed by cross-linking agents. 
These polymers possess optimal polarity to make sure 
that they permit sufficient wetting by the mucus and 
optimal fluidity that permits the mutual adsorption and 
interpenetration of polymer and mucus to take place. 
Mucoadhesive polymers that adhere to the musin 
epithelial surface can be conveniently divided into three 
broad classes: 
 Polymers that become sticky when placed in water 
and owe their mucoadhesion to stickiness. 
 Polymers that adhere through nonspecific, non 
covalent interactions that is primarily electrostatic 
in nature (although hydrogen and hydrophobic 
bonding may be significant). 
 Polymers that bind to specific receptor site on tile 
self surface. All three polymer types can be used 
for drug delivery.  
Uniqueness of mucoadhesive polymer: 
The polymer and its degradation products should be 
nontoxic and should be non absorbable from the 
gastrointestinal tract. 
2. It should be nonirritant to the mucous membrane. 
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3. It should preferably form a strong non-covalent bond 
with the mucin-epithelial cell surfaces. 
4. It should adhere quickly to most tissue and should 
possess some site-specificity. 
5. It should allow daily incorporation to the drug and 
offer no hindrance to its release. 
6. The polymer must not decompose on storage or 
during the shelf life of the dosage form. 
7. The cost of polymer should not be high so that the 
prepared dosage form remains competitive. 
Mucoadhesion Theories: 
Mucoadhesion is a complex process and numerous 
theories have been proposed to explain the mechanisms 
involved. These theories include: 
 Wetting theory 
 Diffusion theory 
 Fracture theory 
 Adsorption theory 
 Electronic theory 
Mechanism of mucoadhesion: 
The process of mucoadhesion following nasal 
administration relates to the interaction between the 
mucoadhesive polymer and the mucus secreted by the 
sub-mucosal glands. The sequential events that occur 
during the mucoadhesion include the proper wetting and 
swelling of the polymer, and intimate contact between 
the polymer and the nasal mucosa. Then, the swollen 
mucoadhesive polymer penetrates into the tissue 
crevices followed by the interpenetration between the 
polymer chains and the protein chains of the mucus 
(Figure1). 
To obtain sufficient absorption of drugs, firstly, the 
formulation should spread well on the nasal mucosa. 
Therefore, the spreadability is very important for the 
liquid mucoadhesive formulation, so does the 
flowability and wettablility for the solid mucoadhesive 
formulation. 
Hydration of the polymer (swelling) plays a very 
important role in mucoadhesion, through which 
the polymer chains are liberated and interact with the 
biological tissue. During hydration, there is a 
dissociation of hydrogen bonds of the polymer chains. 
When the polymer– water interaction becomes greater 
than the polymer– polymer interaction, adequate free 
polymer chains will be available for interaction between 
the polymer and the biological tissue. The Vander 
Waals, hydrogen, hydrophobic, and electrostatic forces 
between the polymer and the biological tissue 
(including the mucus), which form secondary chemical 
bonds, result in the adhesion of polymer to the mucosa. 
There is a critical degree of hydration required for 
optimum mucoadhesion. The incomplete hydration 
because of the lack of the water leads to incomplete 
liberation of the polymer chains.
17, 18, 19, 20, 21, 22, 
 
 
 
 
Figure 1: Schematic representation of the process of mucoadhesion on the nasal mucosa surface 
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Figure 2: Schematic representation of the mucoadhesive intranasal formulation. 
 
Nasal anatomy and physiology:
 23, 24
 
The nasal cavity is divided into two halves by the nasal 
septum and extends posteriorly to the nasopharynx, 
while the most anterior part of the nasal cavity, the 
nasal vestibule, opens to the face through the nostril 
(Figure 1). The atrium is an intermediate region 
between the vestibule and the respiratory region. The 
respiratory region, the nasal conchae or turbinates, 
which occupies the major part of the nasal cavity, 
possesses lateral walls dividing it into 3 sections: 
 The superior 
 Middle 
 Inferior nasal turbinates.  
The nasal vestibule has the smallest cross-sectional area 
in the respiratory tract (approximately 0.3 cm2 on each 
side) that extends from the entrance of nostril, which is 
guarded by vibrissae (hairs), to the anterior end of the 
inferior turbinate. The area from the anterior ends of the 
turbinate to the anterior portion of the nasopharynx 
constitutes the main nasal passages.The epithelial cells 
in the nasal vestibule are stratified, squamous and 
keratinized with sebaceous glands. Due to its nature, the 
nasal vestibule is very resistant to dehydration and can 
withstand noxious environmental substances and limits 
permeation of substances. Microvilli are found on the 
columnar cell, which increases the surface area 
available for absorption. The nasal mucosa is highly 
vasculature, superficial and deep layers of arterioles 
supply the lamina propria and between the venules and 
capillaries. Most of the area of the nasal cavity serves 
the function of cleaning the air we breathe before it 
reaches the lungs. It does this with the help of the 
respiratory mucosa, which lines the walls of the nasal 
cavity. Within this mucosa, small, hair-like cilia move 
in a wave-like motion, moving mucus to the back of the 
throat. 
 
 
 
Figure: 3 Diagram of nasal route 
 
Compatibility of Nasal route with diverse dosage 
forms: 
The ultimate dosage form worn for nasal drug delivery 
is preferred after contemplation of a wide range of 
factors, covering patient convenience, efficiency of 
drug delivery and formulation reasons. Nasal sprays, 
squeeze bottles, and liquid droppers are some of the 
more common liberation methods that can be seen as 
nasal dosage forms. There are three chief ways of 
depositing inhaled particles or the nasal lining: 
impaction, sedimentation and diffusion. Impaction 
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occurs when there is a change in direction of the airflow 
- as happens when inspired air passes through the nasal 
valve – and the inertia of large or fast-moving particles 
carries them in their original direction. Sedimentation 
happens when the moving slowly and the particles settle 
slowly under the force of gravity. The final method of 
deposition diffusion occurs by Brownian motion and is 
thus limited to very small particles (< 0.5 mm). Nasal 
dosage forms will usually contain the drug in a liquid or 
powder formulations delivered by a pressurized or 
pump system.  
Solid dosage forms: 
Powders: 
Dry powder formulations can also avoid the utilization 
of preservatives and freeze storage, because they do not 
support microbial growth and are more stable than 
solution. For these reasons, the dried powder is the most 
commonly studied formulation for the nasal drug 
delivery, including small hydrophobic drugs, peptide 
drugs, and vaccine. Prepared dry powder nasal 
influenza vaccine formulation by using spray-freeze-
drying method; the results indicated that the powders 
were amorphous and more stable with respect to liquid 
formulations. In vivo experiments demonstrated that the 
powders significantly increased residence time in rats 
and elicit enhanced serum and mucosal antibody 
response. Powder dosage forms of drugs for nasal 
administration offer several advantages over liquid 
formulations. In the powder form, the chemical stability 
of the drug is increased, a preservative in the 
formulation is not required, and it is possible to 
administer larger doses of drugs. Powder form is 
suitable for number of non-peptide drugs and is well 
suited for peptide drugs. Polymer-based powder 
formulations show no adhesion until their absorption of 
mucus occurs on the nasal mucosa surface. This allows 
easy application to the nasal cavity by metered dose in 
sufflation even if the polymer is highly mucoadhesive. 
In addition, liquid preparations are more easily cleared 
to the nasopharynx and oropharynx from where they 
enter the posterior part of the tongue. Therefore, 
administration of nasal powders may increase patient 
compliance, especially if the smell and taste of the 
delivered drug is unacceptable. After getting in contact 
with the nasal mucosa, polymer-based powders are 
believed to form a viscous gel following absorbing 
water from the nasal mucus. Then, the free polymer 
chains penetrating into the tissue crevices can hold back 
the ciliary movement, which will increase the retention 
time of the drugs in the nasal cavity.
25, 26, 27, 28 
 
Table 1: Summing up of some nasal drug delivery studies where solid doage from were employed 
29-33
 
S.No Active pharmaceutical 
ingredient 
Dosage form Bioadhesive polymer Animal species 
01. Dopamine Powder Hydroxy propyl cellulose Rabbits 
02. Gentamycin Powder Chitosan Rabbits 
03. Pentazocin Powder Chitosan Rabbits 
04. Apomorphine Powder Carbopol971p Rabbits 
05. Desmopressin Powder Starch Sheeps 
06. Insulin Powder Starch Sheeps 
07. Insulin Powder Carbopol 974p Rabbits 
08. Morphine HCl Powder Strach microsphere Sheeps 
09. Pentazocin Powder Chitosan microspheres Rabbits 
10. Gentamicin Powder Chitosan Rabbits 
11. Insulin Powder Aminated gelatin microspheres Rabbits 
12. Insulin Powder Strach Rats 
 
Liquid dosage forms: 
Solutions: 
They give a better absorption of drug by directing the 
formulation into the anterior part of the cavity and 
covering a large part of the nasal mucosa. The drug 
solutions are nasally administered as nasal drops, 
sprays, and as metered dose nebulizer. The dose of the 
active ingredient administered depends upon the 
volume of drug and the concentration of drug in the 
formulation. The therapeutic levels of nitroglycerine, 3 
ng/ml in central venous blood, 1.7 ng/ml in arterial 
blood, and 0.4 ng/ml in peripheral venous blood were 
achieved within 2 minutes following intranasal 
administration of 0.8 mg/ml of nitroglycerine in normal 
saline. The effect of formulation variables such as dose 
of active ingredient, pH of the solution, and its 
osmolarity on nasal absorption has been reported by 
various researchers. Liquid formulations used for nasal 
drug delivery are usually aqueous solutions of the drug 
and thus have the general benefits and drawbacks of 
pharmaceutical solutions. They are relatively simple to 
develop and manufacture compared to solid dosage 
forms but often have a lower microbiological and 
chemical stability, requiring the use of various 
preservatives. Squeezed bottles are often used for nasal 
decongestants and work by spraying a partially 
atomized jet of liquid into the nasal cavity.  
Suspensions: 
Suspensions for nasal administration are prepared by 
suspending the micronized drug in a liquid diluents or 
carrier suitable for application to the nasal mucosa. The 
preparation of suspension form gave a better insulin 
uptake and blood glucose reduction compared with that 
from the solution. 
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Table 2: Summing up of some nasal drug delivery studies where liquid dosage form were employed 
34-42
 
S.No Active pharmaceutical 
ingredient 
Dosage form Bioadhesive polymer Animal species 
01. Insulin  Liquid Chitosan Human 
02. Levonorgestrel Liquid Chitosan Rats 
03. Salmon calcitonin Liquid Chitosan Rats 
04. Insulin Liquid Chitosan/EDTA Rats 
05. Goserelin Liquid Chitosan microspheres Sheeps 
06. Metoclopramide Liquid Degradable starch 
microspheres 
Human 
07. Dopamine Liquid HPC Dogs 
08. Metoclopramide Solution Carbopol 981p Sheeps 
09. Keterolac tromethamine Spray MCC Rabbits 
10. Insulin Spray MCC Rabbits 
11. Midazolam Spray HPMC Humans 
12. Metaclopramide Spray Chitosan Rabbits 
 
Semi-solid dosage forms: 
A gel is a soft, solid or solid-like material consisting of 
two or more components, one of which is a liquid, 
present in substantial quantity. A gel should, on a time 
scale of seconds, not flow under the influence of its own 
weight. The solid-like characteristics of gels can be 
defined in terms of two dynamic mechanical properties: 
An elastic modulus, which exhibits a pronounced 
plateau extending to time at least of the order of second; 
and a viscous modulus. The first biological uses of gels 
were presented by the institute for Macromolecular 
Chemistry in Prague in 1960 and involved the 
manufacturing of contact lenses, arteries, etc. 
 Gelation occurs through the cross-linking of 
polymer chains, something that can be achieved by 
covalent bond formation. 
 Non-covalent bond formation. Gels have been used 
for the delivery of drugs for both systemic and 
local actions. Many different methods using gels 
have been reported, including subcutaneous 
delivery for sustained release, buccal delivery, 
deliveries to the stomach, colon, rectum, vagina, 
and nasal. 
Gel formulations with suitable rheological properties 
increase the contact time with the mucosa at the site of 
absorption. The increased contact time is caused by the 
mucoadhesive properties of the polymer in the gel and 
by the rheological properties of the formulation 
reducing the clearance by the nasal and ocular 
protective mechanisms. 
 
Table 3: Summing up of some nasal drug delivery studies where semi-solid dosage form were employed
43-44
 
S.No Active pharmaceutical 
ingredient 
Dosage form Bioadhesive polymer Animal species 
01. Ciprofloxacin Gel HPMC Rabbits 
02. Ciprofloxacin Gel MC Rabbits 
03. Ciprofloxacin Gel Tween 80 Rabbits 
04. Metoclopramide Gel Carbopol Rabbits 
 
Bioadhesive polymers used for the delivery through 
nasal route:  
Chitosan: 
Chitosan and its derivatives have been shown to be 
active in enhancing the intranasal drug absorption due 
to their excellent mucoadhesive properties. It was also 
confirmed that coating micro- and nanoparticulates with 
chitosan could improve drug adsorption to mucosal 
surfaces shows various chitosan derivatives used in 
nasal drug delivery system. Chitosan [2-amino-2-
deoxy-(1-4)-β-dglucopyranan] is a linear cationic 
polysaccharide that is obtained by a process of 
deacetylation from chitin, an abundant structural 
polysaccharide in shells of crustacean such as lobsters, 
shrimps, and crabs. Because of the NH2 groups 
resulting from the deacetylation process, chitosan is 
insoluble at neutral and alkaline pH. However, it can 
form water-soluble salts with inorganic and organic 
acids including glutamic acid, hydrochloric acid, lactic 
acid, and acetic acid.
45, 46, 47 
Literature review of chitosan based delivery of drugs 
through for nasal route: 
 Soane et al. have reported that chitosan 
microspheres and solutions revealed a three and 
eightfold longer clearance half-lives compared with 
sodium pertechnetate labelled solution in sheep 
nasal cavity, respectively.
48
 
 Thanou et al. reported that the trimethyl chitosan 
was soluble and effective on enhancing intranasal 
absorption even at neutral pH.N-trimethyl chitosan 
hydrochlorides are more mucoadhesive than 
unmodified chitosans and show a higher 
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bioavailability in vivo compared with the 
unmodified chitosans. To improve the poor water 
solubility of chitosan, some derivatives were 
synthesized, such as trimethyl chitosan.
49, 50, 51
 
 Mei et al. reported that the permeation-enhancing 
effect of chitosan increased with increasing 
molecular weight up to Mw 100.
52
 
 Tengamnuay et al. suggested that chitosans should 
differ in their molecular weight by at least two-fold 
in order to have a clearly differentiating effect on 
the nasal absorption enhancement of a kyotorphin 
analogue.
53
 
 Zaki et al. found that there is no significant 
difference between the constants of intranasal 
absorption for metoclopramide HCl administered 
with chitosan high weight (600 kDa) and low 
weight (150 kDa) even though they differ in 
molecular weight by four-fold.
54 
Starch: 
The starch is one of the most widely used mucoadhesive 
carrier for nasal drug delivery, which has been reported 
to be effective on improving the absorption of both 
small hydrophobic drugs and hydrophilic 
macromolecular drugs. Maize starch is the most 
preferred class for pharmaceutical purpose, among 
which the drum-dried waxy maize starch, due to its 
better bioadhesive property, has been considered as the 
best one compared with starch processed through other 
methods.
55 
Starch can be used as nasal drug carrier in the form of 
powders, microspheres, or nanoparticles, among which 
the degradable starch microspheres (DSM), also known 
as SpherexR. 
Literature review of strach based delivery of drugs 
through for nasal route
56, 57, 58, 59
: 
 Bjork and Edman suggested that water uptake by 
DSM and subsequent swelling might cause 
dehydration of the epithelial cells leading to the 
widening of tight junctions and as a consequence 
facilitate the paracellular transport of large 
hydrophilic molecules such as insulin. It was 
suggested that the extent of drug absorption was 
improved even further when DSM were combined 
with the biological enhancers such as 
lysophosphatidylcholine (LPC). DSM can also 
protect the proteins wrapped in it against 
degradation by proteases in the mucosa. 
 Illum et al. have observed that the half-life of 
clearance for DSM was prolonged to 240 minutes 
compared with 15 minutes for the liquid and 
powder control formulations. 
Cellulose derivatives: 
Cellulose derivatives can markedly prolong the 
residence time of drugs in the nasal cavity due to their 
desirable mucoadhesive property. Additionally, due to 
their high viscosity following hydration in the nasal 
cavity, the celluloses can sustain the release of drugs. 
For these reasons, using celluloses as absorption 
enhancer can lead to improved intranasal absorption and 
increased bioavailability. Many references show that the 
celluloses are effective on increasing the intranasal 
bioavailability of small hydrophobic as well as 
hydrophilic macromolecular drugs.
60, 61 
There are many pharmaceutical grade derivatives of 
cellulose widely used in different administration routes. 
Several cellulose derivatives have proved to be effective 
in enhancing the intranasal absorption of drugs, 
including soluble cellulose derivatives such as 
hydroxypropyl methylcellulose (HPMC), 
hydroxypropyl cellulose (HPC), methylcellulose (MC) 
and carboxymethyl cellulose (CMC), and insoluble 
cellulose derivatives such as ethylcellulose (EC) and 
microcrystalline cellulose (MCC).  
Literature review of cellulose derivative based 
delivery of drugs through for nasal route
62
: 
Ikeda et al. involving the intranasal delivery of 
dopamine, the combination of the HPC and azone led to 
an absolute bioavailability of almost 100% whereas it 
was only 25% with HPC alone.
 
Polyacrylates: 
63-66
 
Polyacrylates, capable of attaching to mucosal surfaces, 
can offer the prospects of prolonging the residence time 
of drugs at the sites of drug absorption and ensure 
intimate contact between the formulation and the 
membrane surface. Among the pharmaceutical 
polyacrylates, carbomers and polycarbophil, which 
differ in the cross-linking condition and viscosity, are 
widely used in the nasal mucoadhesive drug delivery 
systems. 
Literature review of polyacrylates based delivery of 
drugs through for nasal route
62
: 
Callens et al. reported that the effect of Carbopol on the 
mucosa is negligible and reversible, no change of the 
epithelium barrier was observed even after a 4-week 
administration of Carbopol-based powder formulation 
in rabbits. 
67, 68 
Another research by Ugwoke et al. showed that the 
Tmax of the Carbopol 971P-containing formulation of 
apomorphine was 52.21 minutes, which represented a 
fivefold improvement compared with that of the 
lactose-containing formulation, whereas the Cmax of 
the Carbopol 971Pcontaining formulation was 330.2 
ng/mL, lower than that of the lactose containing 
formulation, which was 450.7 ng/mL. 
69 
CONCLUSION: 
Mucoadhesive polymers will undoubtedly be utilized 
for the nasal delivery of a wide variety of therapeutic 
compounds. This class of polymers has mammoth 
prospective for the delivery of therapeutic 
macromolecules, genes, and vaccines. Unluckily, only a 
small number of studies have been conducted with new-
generation mucoadhesive polymers for nasal drug 
delivery, and very hardly any papers focus on the 
changes of structure and rheology of the mucus caused 
by the mucoadhesive polymer, and as to what extent the 
interaction between the polymer and the mucus 
influences the release of the drugs including the 
diseased condition. With recent advancements in the 
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fields of biotechnology and cytoadhesion, the authors 
believe that there will be both academic and industrial 
efforts to explore this new area of nasal drug delivery, 
and it might not be too farfetched to envisage more and 
more nasal products that employ mucoadhesive 
polymers. Current use of mucoadhesive polymers to 
increase contact time for a wide variety of drugs and 
routes of administration has shown dramatic 
improvement in both specific therapies and more 
general patient compliance. The general properties of 
these polymers for purpose of sustained release of 
chemicals are marginal in being able to accommodate a 
wide range of physicochemical drug properties. Hence 
mucoadhesive polymers can be used as means of 
improving drug delivery through different routes like 
gastrointestinal, nasal, ocular, buccal, vaginal and 
rectal. Many potential mucoadhesive systems are being 
investigated which may find their way into the market 
in near future. 
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